Bc-NFkB-dODN

Bc-NFkB-dODN is a bifunctional synthetic oligonucleotide conjugate designed to selectively target and inhibit NF-κB signaling in TLR9-positive cells, such as B-cell lymphoma and myeloid cells. Developed by researchers at the City of Hope, the molecule consists of a class-B CpG oligodeoxynucleotide (ODN) moiety, which acts as a TLR9 agonist and delivery vehicle, chemically linked to a stabilized decoy ODN that binds and sequesters NF-κB homo- and heterodimers. This dual-action approach aims to reprogram the immunosuppressive tumor microenvironment by promoting immune activation while simultaneously disrupting constitutive NF-κB survival signaling in malignant cells. In preclinical models of diffuse large B-cell lymphoma (DLBCL), Bc-NFkB-dODN has demonstrated the ability to sensitize tumors to DNA-damaging agents and PARP inhibitors, activate CD8+ T cells, and reduce tumor burden without significant off-target toxicity to T cells.

Other names

bifunctional decoy oligonucleotide NF-κB inhibitor linked to a class-B CpG moietyBifunctional NF-κB Decoy